Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Losartan
Drug ID BADD_D01322
Description Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension.[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.[L7423] When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide].[L7423] Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored.[L7423] Losartan was granted FDA approval on 14 April 1995.[L7423]
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Losartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status Prescription; Discontinued
ATC Code C09CA01
DrugBank ID DB00678
KEGG ID D08146
MeSH ID D019808
PubChem ID 3961
TTD Drug ID D0DD0K
NDC Product Code Not Available
Synonyms Losartan | 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol | DuP-753 | DuP 753 | DuP753 | MK-954 | MK 954 | MK954 | Cozaar | Losartan Potassium | Potassium, Losartan | Losartan Monopotassium Salt | Monopotassium Salt, Losartan | Salt, Losartan Monopotassium
Chemical Information
Molecular Formula C22H23ClN6O
CAS Registry Number 114798-26-4
SMILES CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Capillary fragility increasedC-C motif chemokine 2P14844Not Available26156105
Capillary fragility increasedInterleukin-1 alphaP01583T1634026156105
Capillary fragility increasedInterleukin-10P29456Not Available26156105
Metabolic disorderCytochrome P450 2C9P11712T192449663807; 11434505; 9825828
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Choking22.02.05.0010.000073%Not Available
Cholelithiasis09.03.01.0020.000097%Not Available
Chronic obstructive pulmonary disease22.03.01.0070.000051%Not Available
Circulatory collapse24.06.02.001--Not Available
Coagulopathy01.01.02.0010.000146%Not Available
Colon cancer16.13.01.001; 07.21.01.001--Not Available
Compartment syndrome15.05.05.005; 24.04.05.0060.000049%Not Available
Confusional state17.02.03.005; 19.13.01.001--
Conjunctivitis11.01.06.012; 06.04.01.002--
Constipation07.02.02.001--
Coordination abnormal17.02.02.0040.000049%Not Available
Coronary artery disease24.04.04.006; 02.02.01.001--Not Available
Cough22.02.03.0010.000946%
Crohn's disease10.02.01.005; 07.08.01.015--Not Available
Cutaneous vasculitis24.05.02.004; 23.06.02.001; 10.02.02.003--Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.000097%
Cystitis20.03.02.002; 11.01.14.001--
Death08.04.01.0010.004658%
Decubitus ulcer23.03.11.0060.000073%Not Available
Dehydration14.05.05.001--
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.0010.000097%Not Available
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative23.03.07.001; 10.01.01.004--
Diabetes mellitus14.06.01.001; 05.06.01.0010.000340%Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000073%Not Available
Diabetic neuropathy17.09.04.002; 14.07.04.003; 05.07.04.003--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 19 Pages